X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs BIOCON LTD - Comparison Results

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA BIOCON LTD AJANTA PHARMA/
BIOCON LTD
 
P/E (TTM) x 19.6 96.6 20.3% View Chart
P/BV x 4.5 7.9 57.1% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 AJANTA PHARMA   BIOCON LTD
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
BIOCON LTD
Mar-17
AJANTA PHARMA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1,8181,162 156.5%   
Low Rs1,106483 229.2%   
Sales per share (Unadj.) Rs239.5194.6 123.1%  
Earnings per share (Unadj.) Rs52.834.4 153.4%  
Cash flow per share (Unadj.) Rs59.548.3 123.3%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.1 0.0%  
Book value per share (Unadj.) Rs230.0241.9 95.1%  
Shares outstanding (eoy) m88.77200.00 44.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.14.2 144.5%   
Avg P/E ratio x27.723.9 115.9%  
P/CF ratio (eoy) x24.617.0 144.2%  
Price / Book Value ratio x6.43.4 187.0%  
Dividend payout %02.9 0.0%   
Avg Mkt Cap Rs m129,782164,440 78.9%   
No. of employees `0006.89.2 73.6%   
Total wages/salary Rs m3,7657,470 50.4%   
Avg. sales/employee Rs Th3,128.44,213.9 74.2%   
Avg. wages/employee Rs Th554.0809.0 68.5%   
Avg. net profit/employee Rs Th689.7745.2 92.6%   
INCOME DATA
Net Sales Rs m21,25838,911 54.6%  
Other income Rs m2421,571 15.4%   
Total revenues Rs m21,49940,482 53.1%   
Gross profit Rs m6,5849,795 67.2%  
Depreciation Rs m5962,772 21.5%   
Interest Rs m4260 1.6%   
Profit before tax Rs m6,2268,334 74.7%   
Minority Interest Rs m0163 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5391,616 95.2%   
Profit after tax Rs m4,6866,881 68.1%  
Gross profit margin %31.025.2 123.0%  
Effective tax rate %24.719.4 127.5%   
Net profit margin %22.017.7 124.7%  
BALANCE SHEET DATA
Current assets Rs m12,23640,477 30.2%   
Current liabilities Rs m3,46116,783 20.6%   
Net working cap to sales %41.360.9 67.8%  
Current ratio x3.52.4 146.6%  
Inventory Days Days6060 101.0%  
Debtors Days Days8483 102.0%  
Net fixed assets Rs m11,14045,073 24.7%   
Share capital Rs m1771,000 17.7%   
"Free" reserves Rs m20,23747,377 42.7%   
Net worth Rs m20,41448,377 42.2%   
Long term debt Rs m1021,082 0.0%   
Total assets Rs m24,48693,942 26.1%  
Interest coverage x1,519.433.1 4,596.8%   
Debt to equity ratio x00.4 0.1%  
Sales to assets ratio x0.90.4 209.6%   
Return on assets %19.27.6 252.0%  
Return on equity %23.014.2 161.4%  
Return on capital %30.512.6 241.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m11,66712,988 89.8%   
Fx outflow Rs m1,6167,899 20.5%   
Net fx Rs m10,0525,089 197.5%   
CASH FLOW
From Operations Rs m2,8546,400 44.6%  
From Investments Rs m-2,604-4,985 52.2%  
From Financial Activity Rs m-2-1,775 0.1%  
Net Cashflow Rs m248-473 -52.5%  

Share Holding

Indian Promoters % 73.8 40.4 182.7%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 1.6 8.4 18.5%  
FIIs % 7.6 10.7 71.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 19.9 85.4%  
Shareholders   20,968 109,995 19.1%  
Pledged promoter(s) holding % 4.4 0.0 10,975.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT LTD.  GSK PHARMA  PANACEA BIOTECH  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Energy Stocks Lose(09:30 am)

Asian share markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.4% while the Hang Seng is down 0.5%. The Shanghai Composite is trading up by 0.2%.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jun 25, 2018 11:21 AM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - NATCO PHARMA COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS